Saturday, January 29, 2011

RegenMD - BioTime acquires biotech company assets for $250K

 
MAINTENANCE Feed My Inbox will be undergoing maintenance on Saturday January 29th from approx 8-11 am CST. Emails will be delayed during this time period. We appreciate your patience. More details
 
     
    RegenMD    
   
BioTime acquires biotech company assets for $250K
January 29, 2011 at 2:33 AM
 
Cell Targeting, based in Cleveland, has been conducting research in regenerative medicine, using peptides that can adhere to diseased tissues without ...
See all stories on this topic »
   
   
Stem cell research promising
January 28, 2011 at 11:58 PM
 
Zhou described China's progress after the CAS designated stem cell and regenerative medicine research as one of the country's eight "strategic trailblazing ...
See all stories on this topic »
   
   
University Receives $5.8M for Stem Cell Research
January 28, 2011 at 11:58 PM
 
The California Institute for Regenerative Medicine, aka CIRM, has awarded three grants totaling nearly $5.8 million to researchers at UC San Diego for ...
See all stories on this topic »
   
   
Science Cafe to kick off spring series with 'Tissue Engineering: The Key to ...
January 28, 2011 at 5:10 PM
 
Gabor Forgacs speaking on "Tissue Engineering: The Key to Eternal Life?" In the not-too-distant future, Forgacs says, people will simply walk into a ...
See all stories on this topic »
   
   
Sport Horse Practice Table Topic (AAEP 2010)
January 28, 2011 at 2:21 PM
 
Major topics of discussion included shock wave therapy and regenerative medicine. Attendees credited shock wave therapy as a good management tool for both ...
See all stories on this topic »
   
   
Regenerative medicine startup Cell Targeting sold to BioTime
January 28, 2011 at 2:21 PM
 
Stem cell technology developer Cell Targeting has sold its assets to BioTime (AMEX:BTX) in a deal worth about $2.3 million. BioTime will pay $250000 in cash ...
See all stories on this topic »
   
   
Convergence solves problems that don't fit in one field
January 28, 2011 at 1:35 PM
 
The second approach that we started thinking about really is the epitome of convergence, and that's tissue engineering…. The idea is that you could take ...
See all stories on this topic »
   
   
BioTime Buys Assets from Cell Targeting to Boost Its Regenerative Medicine Focus
January 28, 2011 at 10:32 AM
 
... of a wide array of therapeutic products in the emerging field of regenerative medicine," remarks Michael D. West, Ph.D., president and CEO of BioTime.
See all stories on this topic »
   
   
Nanotope Founder Dr. Sam Stupp Featured in Fast Company's February Issue
January 28, 2011 at 8:37 AM
 
Arrowhead also holds minority investments in Nanotope, a regenerative medicine company and Leonardo Biosystems, a multistage drug delivery company.
See all stories on this topic »
   
   
In vivo assessment of acute UVB responses in normal and Xeroderma Pigmentosum (XP-C) skin-humanized mouse models.
January 28, 2011 at 8:18 AM
 

In vivo assessment of acute UVB responses in normal and Xeroderma Pigmentosum (XP-C) skin-humanized mouse models.

Am J Pathol. 2010 Aug;177(2):865-72

Authors: García M, Llames S, García E, Meana A, Cuadrado N, Recasens M, Puig S, Nagore E, Illera N, Jorcano JL, Del Rio M, Larcher F

In vivo studies of UVB effects on human skin are precluded by ethical and technical arguments on volunteers and inconceivable in cancer-prone patients such as those affected with Xeroderma Pigmentosum (XP). Establishing reliable models to address mechanistic and therapeutic matters thus remains a challenge. Here we have used the skin-humanized mouse system that circumvents most current model constraints. We assessed the UVB radiation effects including the sequential changes after acute exposure with respect to timing, dosage, and the relationship between dose and degree-sort of epidermal alteration. On Caucasian-derived regenerated skins, UVB irradiation (800 J/m(2)) induced DNA damage (cyclobutane pyrimidine dimers) and p53 expression in exposed keratinocytes. Epidermal disorganization was observed at higher doses. In contrast, in African descent-derived regenerated skins, physiological hyperpigmentation prevented tissue alterations and DNA photolesions. The acute UVB effects seen in Caucasian-derived engrafted skins were also blocked by a physical sunscreen, demonstrating the suitability of the system for photoprotection studies. We also report the establishment of a photosensitive model through the transplantation of XP-C patient cells as part of a bioengineered skin. The inability of XP-C engrafted skin to remove DNA damaged cells was confirmed in vivo. Both the normal and XP-C versions of the skin-humanized mice proved proficient models to assess UVB-mediated DNA repair responses and provide a strong platform to test novel therapeutic strategies.

PMID: 20558577 [PubMed - indexed for MEDLINE]

   
   
UCSD stem cell researchers get $5.6 million from state
January 28, 2011 at 6:51 AM
 
The money was among $32.9 million dolled out by the California Institute for Regenerative Medicine to seven nonprofit institutions and three companies. ...
See all stories on this topic »
   
     
 
This email was sent to agupta1213+termsc@gmail.com.
Delivered by Feed My Inbox
PO Box 682532 Franklin, TN 37068
Account Login
Unsubscribe Here Feed My Inbox
 
     

No comments: